Drug
Cenobamate clinical trials
Also written YKP3089 and Xcopri.
- studies test it
- 18
- open now
- 3
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the Cenobamate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 1
SK Life Science, Inc. (15) · Ono Pharmaceutical Co. Ltd (2) · Brigham and Women's Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Cenobamate is read from its arms, and is right about nine times in ten.
Testing it · 18
- Cenobamate in the Intensive Care UnitNot yet recruitingEarly Phase 1Brigham and Women's HospitalNCT06352723Written as Cenobamate
- ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.RecruitingPhase 3Ono Pharmaceutical Co. LtdNCT06579573Written as Cenobamate
- Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresRecruitingPhase 2Ono Pharmaceutical Co. LtdNCT06590896Written as Cenobamate
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresCompletedPhase 3SK Life Science, Inc.NCT05067634Written as Xcopri
- Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyActive, not recruitingPhase 4SK Life Science, Inc.NCT06453213Written as Cenobamate
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresCompletedPhase 3SK Life Science, Inc.NCT03678753Written as Cenobamate
- Cenobamate Open-Label Extension Study for YKP3089C025CompletedPhase 3SK Life Science, Inc.NCT03961568Written as Cenobamate
- Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSCompletedPhase 3SK Life Science, Inc.NCT04557085Written as Cenobamate
- Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresCompletedPhase 1SK Life Science, Inc.NCT04903314Written as Xcopri
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedPhase 2SK Life Science, Inc.NCT01866111Written as YKP3089
- A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug UsersCompletedPhase 1SK Life Science, Inc.NCT03509285Written as Cenobamate
- A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered OrallyCompletedPhase 1SK Life Science, Inc.NCT05572255Written as Cenobamate
- Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug InteractionsCompletedPhase 1SK Life Science, Inc.NCT03234699Written as Cenobamate
- Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and TabletCompletedPhase 1SK Life Science, Inc.NCT04690751Written as Cenobamate 200Mg Tab Fasted
- Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedPhase 3SK Life Science, Inc.NCT02535091Written as YKP3089
- Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic ImpairmentCompletedPhase 1SK Life Science, Inc.NCT04791553Written as Cenobamate
- Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedPhase 2SK Life Science, Inc.NCT01397968Written as YKP3089
- Efficacy of YKP3089 in Patients With Photosensitive EpilepsyCompletedPhase 2SK Life Science, Inc.NCT00616148Written as YKP3089
Codes
What other systems call Cenobamate · ClinicalTrials.gg INT001213
- MeSH (NLM) C000654784CenobamateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P85X70RZWSCENOBAMATEConfirmed FDA, NLM, Wikidata
- RxNorm 2265690One source FDA
- Wikidata Q27286352cenobamateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174837CenobamateOne source FDA
- DrugBank DB06119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654784 | Cenobamate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P85X70RZWS | CENOBAMATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2265690 | — | One source FDA |
| Wikidata | Q27286352 | cenobamate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174837 | Cenobamate | One source FDA |
| DrugBank | DB06119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.